There’s a new way to kill tumors

by eradicating the immune suppressive nature of the TME

IO Biotech is a Phase 3 company leading the way

About us

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win® technology platform.

Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Latest news

IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022

IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022